biostudies-literatureUnknown20(1)Alexandra Echeverria Proano DGlaxoSmithKlinePhase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These pivotal trials did not enroll participants from mainland China where RZV is licensed, therefore similar clinical data are missing for this population. In this phase IV observer-blind study (NCT04869982) conducted between 2021 and 2023 in China, immunocompetent and medically stable ≥ 50-year-olds were randomized 1:1 to receive two RZV or placebo doses, 2 months apart. This study assessed the VE (overall, as confirmatory objective, and descriptively by age category [50-69-year-olds/≥ 70-year-olds]), reactogenicity, and safety of RZV in this ChinesHuman vaccines & immunotherapeutics2351584https://www.ebi.ac.uk/biostudies/studies/S-EPMC11253707biostudies-literatureEfficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.PMC11253707Zoster-076 Study GroupZhuoying HXiang GJia LJing WSoni JPengfei JYonggen JQi ZSheng LShan ZQiang GZhenhui XHongmei LZhi LEnmao CZhu FJinyan CSun XAlexandra Echeverria Proano DAli SOZoco JLu HZhizhou SParmar NJiahong ZHong PJiaxi DfalseEfficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These pivotal trials did not enroll participants from mainland China where RZV is licensed, therefore similar clinical data are missing for this population. In this phase IV observer-blind study (NCT04869982) conducted between 2021 and 2023 in China, immunocompetent and medically stable ≥ 50-year-olds were randomized 1:1 to receive two RZV or placebo doses, 2 months apart. This study assessed the VE (overall, as confirmatory objective, and descriptively by age category [50-69-year-olds/≥ 70-year-olds]), reactogenicity, and safety of RZV in this Chines2024-01-01T00:00:00Z2024 Dec2026-06-02T11:51:40.438Z2025-04-04T15:02:19.236ZS-EPMC112537073883817010.1080/21645515.2024.2351584